Skip to main content

Individual Drug Analyses

This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present. 

The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis. 

Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.

Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.

FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources

Title Medical Product Outcomes Date
Outpatient Utilization of COVID-19 Treatments Under Emergency Use Authorization (EUA): A Simplified Descriptive Analysis for Paxlovid and other EUA Drugs
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
bebtelovimab,
casirivimab imdevimab,
molnupiravir,
nirmatrelvir and ritonavir,
remdesivir
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: An Updated Descriptive Analysis
Descriptive
mometasone sinus implant
Characterization of Dispensing Patterns of Baricitinib, Ritlecitinib, and Upadacitinib in Patients with Alopecia, Crohn's Disease, Ulcerative Colitis, and Inflammatory Bowel Disease: A Descriptive Analysis
Descriptive
baricitinib,
ritlecitinib,
upadacitinib
Utilization of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis
TriNetX Analysis
non-insulin antidiabetics
Demographic Characteristics of Incident Users of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis
TriNetX Analysis
non-insulin antidiabetics
Clinical Characteristics of Incident Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in TriNetX: A Descriptive Analysis
TriNetX Analysis
glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis
Descriptive
combined hormonal contraceptives (CHCs),
progestin-only contraceptives (POCs)
Risk of Severe Hyperglycemia Following Systemic Corticosteroids and Azithromycin Use in COVID-19 Patients with Type 2 Diabetes: A Sequential Surveillance Analysis
Prospective Sequential Inferential
azithromycin,
corticosteroids
severe hyperglycemia
Corticosteroid Utilization Patterns in Hospitalized Patients With and Without a COVID-19 Diagnosis in TriNetX: A Descriptive Analysis
TriNetX Analysis
Occurrence of Absolute Neutrophil Count (ANC) Monitoring and Neutropenia Following Clozapine Use in Patients from Sentinel Data Partners that Curate ANC Laboratory Results: A Descriptive Analysis
Descriptive
adherence to absolute neutrophil count (ANC) monitoring
neutropenia